Literature DB >> 19389182

Understanding and treating patients with alcoholic cirrhosis: an update.

Giovanni Addolorato1, Marcia Russell, Emanuele Albano, Paul S Haber, Jack R Wands, Lorenzo Leggio.   

Abstract

Alcoholic cirrhosis represents the terminal stage of alcoholic liver disease (ALD) and one of the main causes of death among alcohol abusers. The aim of this review was to provide an update on alcoholic cirrhosis, with an emphasis on recent findings. Increased alcohol consumption in developing countries is expected to increase cirrhosis mortality. There is a need, therefore, to develop new approaches to the prevention of ALD, including more attention to co-factors that may increase risk of ALD (i.e., obesity and diabetes, chronic HCV infection, and smoking). Furthermore, a better understanding of the pathological mechanisms on the basis of alcohol cirrhosis represents a cornerstone in order to develop new pharmacological treatments. Inflammatory and immune responses along with oxidative stress and alterations in adipokine secretion might contribute in different ways to the evolution of alcohol-induced fibrosis/cirrhosis. As of this date, patients with severe alcoholic hepatitis with a Maddrey Discriminant Factor (MDF) 32 should be offered pentoxifylline and/or corticosteroids unless contraindications exist. For ambulatory patients, S-adenosylmethionine (SAMe) may be considered in a motivated patient with nutritional support. Current studies do not support use of anti-tumor necrosis factor (TNF)-alpha antibody. Finally, achieving total alcohol abstinence should represent the main aim in the management of patients affected by any stage of cirrhosis. In the last decades, several drugs able to increase abstinence and prevent alcohol relapse have been evaluated and some of them have obtained approval for alcohol dependence. Patients with alcoholic cirrhosis; however, are usually excluded from such treatments. A recent study demonstrated the efficacy and safety of baclofen in inducing and maintaining alcohol abstinence in cirrhotic alcohol-dependent patients with cirrhosis. All together the information available suggests the need of a multimodal approach in the clinical management of these patients.

Entities:  

Mesh:

Year:  2009        PMID: 19389182     DOI: 10.1111/j.1530-0277.2009.00956.x

Source DB:  PubMed          Journal:  Alcohol Clin Exp Res        ISSN: 0145-6008            Impact factor:   3.455


  9 in total

Review 1.  Pharmacotherapy for alcoholic patients with alcoholic liver disease.

Authors:  Cynthia L Vuittonet; Michael Halse; Lorenzo Leggio; Samuel B Fricchione; Michael Brickley; Carolina L Haass-Koffler; Tonya Tavares; Robert M Swift; George A Kenna
Journal:  Am J Health Syst Pharm       Date:  2014-08-01       Impact factor: 2.637

Review 2.  Building better strategies to develop new medications in Alcohol Use Disorder: Learning from past success and failure to shape a brighter future.

Authors:  Nazzareno Cannella; Massimo Ubaldi; Alessio Masi; Massimo Bramucci; Marisa Roberto; Angelo Bifone; Roberto Ciccocioppo
Journal:  Neurosci Biobehav Rev       Date:  2019-05-18       Impact factor: 8.989

3.  Upregulation of Kupffer cell α2A-Adrenoceptors and downregulation of MKP-1 mediate hepatic injury in chronic alcohol exposure.

Authors:  Michael A Ajakaiye; Asha Jacob; Rongqian Wu; Mian Zhou; Youxin Ji; Weifeng Dong; Zhimin Wang; Xiaoling Qiang; Wayne W Chaung; Jeffrey Nicastro; Gene F Coppa; Ping Wang
Journal:  Biochem Biophys Res Commun       Date:  2011-05-07       Impact factor: 3.575

4.  Treatment of alcoholic liver disease.

Authors:  Thomas H Frazier; Abigail M Stocker; Nicole A Kershner; Luis S Marsano; Craig J McClain
Journal:  Therap Adv Gastroenterol       Date:  2011-01       Impact factor: 4.409

Review 5.  Bench-to-beside review: acute-on-chronic liver failure - linking the gut, liver and systemic circulation.

Authors:  Len Verbeke; Frederik Nevens; Wim Laleman
Journal:  Crit Care       Date:  2011-10-25       Impact factor: 9.097

Review 6.  Treatment options for alcoholic and non-alcoholic fatty liver disease: A review.

Authors:  Sukhpreet Singh; Natalia A Osna; Kusum K Kharbanda
Journal:  World J Gastroenterol       Date:  2017-09-28       Impact factor: 5.742

7.  Red Quinoa Bran Extract Prevented Alcoholic Fatty Liver Disease via Increasing Antioxidative System and Repressing Fatty Acid Synthesis Factors in Mice Fed Alcohol Liquid Diet.

Authors:  Ting-An Lin; Bo-Jun Ke; Shih-Cheng Cheng; Chun-Lin Lee
Journal:  Molecules       Date:  2021-11-18       Impact factor: 4.411

8.  Effects of pentoxifylline on renal structure after urethral obstruction in rat: A stereological study.

Authors:  Mehdi Shirazi; Ali Noorafshan; Amir Farrokhi
Journal:  Cent European J Urol       Date:  2011-03-18

9.  Noninvasive 40-Hz Light Flicker Rescues Circadian Behavior and Abnormal Lipid Metabolism Induced by Acute Ethanol Exposure via Improving SIRT1 and the Circadian Clock in the Liver-Brain Axis.

Authors:  Youli Yao; Wenjiang Zhang; Ruibo Ming; Qiyu Deng; Along Zuo; Shengli Zhang; Ying Ying; Yingying Zhao; Junxian Ma
Journal:  Front Pharmacol       Date:  2020-03-25       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.